Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

Since April 2011, he has also been the Chairman of Genzyme. In 2011, net sales reached €33,389 million, +3.2% on a reported basis, +5.3% at constant exchange rates (CER) versus 2010. Sanofi has ...

In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for ...

Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Prof ...

After hours: February 21 at 7:05:16 PM EST Loading Chart for IGMS ...